Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia

This study is testing a chemotherapy combination called CLAGE-Ven (cladribine, cytarabine, gemtuzumab ozogamicin, and venetoclax) followed by a reduced-intensity bone marrow transplant (stem cell transplant) in people with refractory or relapsed acute myeloid leukaemia (AML) — a type of blood cancer — that has not responded to standard treatment. **You may be eligible if...** - You have AML that has not gone into remission after two rounds of chemotherapy, or that has relapsed within 6 months, or has relapsed and not responded to re-induction - You have more than 5% leukaemia cells in your bone marrow - You have a suitable bone marrow donor available (matched sibling, unrelated, or half-matched family donor) - You do not have an active serious infection **You may NOT be eligible if...** - Your liver function or bilirubin levels are significantly abnormal - You do not have a suitable bone marrow donor - You have an active uncontrolled infection Talk to your doctor to see if this trial is right for you.